Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials…
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in…
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one…
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics…
TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity…
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced…
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T…